Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies

被引:375
作者
Ehrenfest, David M. Dohan [1 ,3 ,4 ]
de Peppo, Giuseppe M. [1 ]
Doglioli, Pierre [2 ]
Sammartino, Gilberto [3 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Biomat, S-41390 Gothenburg, Sweden
[2] Jules Ferry Inst, Cell Culture Lab, Cannes, France
[3] Univ Naples Federico II, Dept Odontostomatol & Maxillofacial Sci, Naples, Italy
[4] AP HP, Fdn Res LoB5, Paris, France
关键词
Coagulation; drug delivery; fibrin; growth factors; platelet concentrate; platelet-rich fibrin; platelet-rich plasma; PLASMA-RICH; KIT; MECHANISM; SYSTEM; CELLS; PRGF;
D O I
10.1080/08977190802636713
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platelet concentrates for surgical topical applications are nowadays often used, but quantification of the long-term growth factor release from these preparations in most cases is impossible. Indeed, in most protocols, platelets are massively activated and there is no significant fibrin matrix to support growth factor release and cell migration. Choukroun's platelet-rich fibrin (PRF), a second generation platelet concentrate, is a leucocyte- and platelet-rich fibrin biomaterial. Here, we show that this dense fibrin membrane releases high quantities of three main growth factors (Transforming Growth Factor b-1 (TGF beta-1), platelet derived growth factor AB, PDGF-AB; vascular endothelial growth factor, VEGF) and an important coagulation matricellular glycoprotein (thrombospondin-1, TSP-1) during 7 days. Moreover, the comparison between the final released amounts and the initial content of the membrane (after forcible extraction) allows us to consider that the leucocytes trapped in the fibrin matrix continue to produce high quantities of TGF beta-1 and VEGF during the whole experimental time.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 37 条
[1]  
Anitua E, 1999, INT J ORAL MAX IMPL, V14, P529
[2]   Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers [J].
Anitua, Eduardo ;
Aguirre, Jose J. ;
Algorta, Jaime ;
Ayerdi, Eduardo ;
Cabezas, Ana I. ;
Orive, Gorka ;
Andia, Isabel .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, 2008, 84B (02) :415-421
[3]   The potential impact of the preparation rich in growth factors (PRGF) in different medical fields [J].
Anitua, Eduardo ;
Sanchez, Mikel ;
Orive, Gorka ;
Andia, Isabel .
BIOMATERIALS, 2007, 28 (31) :4551-4560
[4]   Comparison of three different preparations of platelet concentrates for growth factor enrichment [J].
Appel, TR ;
Pötzsch, B ;
Müller, F ;
von Lindern, JJ ;
Bergé, SF ;
Reich, RH .
CLINICAL ORAL IMPLANTS RESEARCH, 2002, 13 (05) :522-528
[5]   Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13 [J].
Bonnefoy, A ;
Daenens, K ;
Feys, HB ;
De Vos, R ;
Vandervoort, P ;
Vermylen, J ;
Lawler, J ;
Hoylaerts, MF .
BLOOD, 2006, 107 (03) :955-964
[6]  
Braccini F, 2007, Rev Laryngol Otol Rhinol (Bord), V128, P255
[7]   Effects of activated platelet concentrates on human primary cultures of fibroblasts and osteoblasts [J].
Cenni, E ;
Ciapetti, G ;
Pagani, S ;
Perut, F ;
Giunti, A ;
Baldini, N .
JOURNAL OF PERIODONTOLOGY, 2005, 76 (03) :323-328
[8]   Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part V: Histologic evaluations of PRF effects on bone allograft maturation in sinus lift [J].
Choukroun, J ;
Diss, A ;
Simonpieri, A ;
Girard, MO ;
Schoeffler, C ;
Dohan, SL ;
Dohan, AJJ ;
Mouhyi, J ;
Dohan, DM .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2006, 101 (03) :299-303
[9]  
Choukroun J., 2001, Implantodontie, V42, P55, DOI DOI 10.1051/MBCB/2013074
[10]  
Choukroun J I, 2007, Rev Laryngol Otol Rhinol (Bord), V128, P27